Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The invention provides anti-idiotypic antibodies against anti-PD-L1 antibodies and methods of using the same.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The present invention provides anti-HtrA1 antibodies (including bispecific anti-HtrA1 anti-Factor D antibodies) and methods of making and using the same, for example, in methods of treating HtrA1-associated disorders, ocular disorders, and/or complement-associated disorders.

Abstract: The PENT value for a resin may be estimated within ±10% by determining the % of heat flow to melt a fraction of a polymer above or below a set point and comparing it to a graph or algorithm of PENT values related to the % of heat flow to melt entire sample for a number of resins made using the same catalyst system. In a similar manner one may estimate the process conditions to prepare a polymer having a target PENT value based on the conditions used to prepare the samples for the graph or algorithms. The invention provides a simple procedure that may be used at a manufacturing site to estimate PENT values.

Abstract: The PENT value for a resin may be estimated within ±10% by determining the % of heat flow to melt a fraction of a polymer above or below a set point and comparing it to a graph or algorithm of PENT values related to the % of heat flow to melt entire sample for a number of resins made using the same catalyst system. In a similar manner one may estimate the process conditions to prepare a polymer having a target PENT value based on the conditions used to prepare the samples for the graph or algorithms. The invention provides a simple procedure that may be used at a manufacturing site to estimate PENT values.

Abstract: Use is provided for a 7&agr;-hydroxy or 7-oxo substituted 3&bgr;-hydroxy-steroid possessing the carbon skeleton of cholesterol, androsterone, pregnenolone or estradiol, or an analogue thereof substituted independently at one or both of the 7- and 3-positions with an ester or ether group, in the manufacture of a pharmaceutical composition for the therapy of neuropsychiatric, immune and/or endocrine disorders or for inducing cognitive enhancement. Uses for Cyp7b enzymes in producing such steroids is also provided together with various novel steroids and test kits and methods for diagnosing the disorders.